Skip to main content
Premium Trial:

Request an Annual Quote

Paul Billings

Natera has appointed Paul Billings as its chief medical officer and senior vice president of medical affairs, where he will help lead efforts across the firm's reproductive health, oncology, and new emerging businesses. Billings is a board-certified internist and clinical geneticist with more than 30 years of experience in genomics and molecular medicine, having held academic and research appointments at Harvard University, UC San Francisco, Stanford University, and UC Berkeley.

Prior to joining Natera, Billings was chief medical officer of Life Technologies, consulting CMO of the genetic sciences division of Thermo Fisher Scientific, and senior physician at Laboratory Corporation of America. He has served on the scientific advisory board of the US Food and Drug Administration, the genomic medicine advisory committee at the Department of Veterans Affairs, and the HHS Secretary’s Advisory Committee on Genomics, Health and Society. His work formed the basis of the Genetic Information Nondiscrimination Act of 2008 (GINA).

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.